Novo Nordisk shares fall on latest trial results for new obesity drug
Novo’s share price fell 8 per cent on Monday, having previously dived in December after a late-stage trial of CagriSema in overweight or obese people without diabetes found they lost an average of ...
BioSpace51m
Deep Dive: Cardiovascular Disease Back in the Spotlight
In this deep dive, BioSpace explores the diverse therapeutic modalities now in development, as well as the opportunities and ...
Devdiscourse55m
Eli Lilly's Global Expansion Plan for Blockbuster Drug Mounjaro
Eli Lilly plans to release its diabetes and weight-loss drug, Mounjaro, in major global markets like China, India, Brazil, ...
Investor's Business Daily on MSN58m
Novo Nordisk Dives 9%. Why Eli Lilly Now Has The Upper Hand.
Novo Nordisk stock tumbled Monday after its experimental weight-loss drug failed to top its rival from Eli Lilly in a Phase 3 study.